Physician profile
Lynda M Smith Harris
NPI 1831272947
$6,712.13
in general payments reported to CMS, 2019-2025
18 companies · $742 in 2025
The $742 reported for 2025 was more than what 78% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $502 · 2021: $876 · 2022: $1,509 · 2023: $1,197 · 2024: $1,786 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.07 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,399.94 | 2019-2024 | Austedo, Austedo Xr, Uzedy |
| Abbvie INC. | $1,219.97 | 2020-2025 | Vraylar, Mavyret |
| Neurocrine Biosciences, INC. | $1,092.07 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $861.70 | 2021-2025 | Caplyta |
| Lundbeck LLC | $545.40 | 2021-2025 | Abilify Maintena, Rexulti |
| Otsuka America Pharmaceutical, INC. | $517.27 | 2020-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $259.31 | 2021-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $202.40 | 2021-2024 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $142.83 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $117.16 | 2023-2025 | Auvelity |
| Indivior INC. | $109.50 | 2020-2023 | Perseris |
| Noven Therapeutics, LLC | $107.35 | 2020-2021 | |
| Pfizer INC. | $34.44 | 2023 | |
| Merck Sharp & Dohme LLC | $24.41 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Glaxosmithkline, LLC. | $24.07 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $21.25 | 2024 | Fanapt |
| Allergan, INC. | $17.74 | 2020 | |
| Orexo US, INC. | $15.32 | 2025 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynda Smith Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.